Published in Lancet Oncol on February 01, 2013
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature (2014) 3.34
Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol (2014) 1.64
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol (2014) 1.63
What have we learned from cancer immunotherapy in the last 3 years? J Transl Med (2014) 1.52
Current approaches to the treatment of metastatic brain tumours. Nat Rev Clin Oncol (2014) 1.21
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer (2014) 1.14
Genetic-based prediction of disease traits: prediction is very difficult, especially about the future. Front Genet (2014) 1.12
Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res (2013) 1.12
Emerging targeted therapies for melanoma treatment (review). Int J Oncol (2014) 1.10
Conjunctival melanomas harbor BRAF and NRAS mutations--Letter. Clin Cancer Res (2013) 1.10
Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ. Cancer Res (2014) 1.10
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res (2015) 1.09
Selective anti-cancer agents as anti-aging drugs. Cancer Biol Ther (2013) 1.06
The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas. Front Oncol (2013) 0.98
Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther (2014) 0.92
Novel anti-melanoma treatment: focus on immunotherapy. Chin J Cancer (2014) 0.88
Covalent small molecule inhibitors of Ca(2+)-bound S100B. Biochemistry (2014) 0.88
Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth. Front Oncol (2015) 0.88
Unsanctifying the sanctuary: challenges and opportunities with brain metastases. Neuro Oncol (2015) 0.87
Application of molecular profiling in clinical trials for advanced metastatic cancers. J Natl Cancer Inst (2015) 0.87
Treatment patterns in patients with metastatic melanoma: a retrospective analysis. J Skin Cancer (2014) 0.86
Do BRAF inhibitors select for populations with different disease progression kinetics? J Transl Med (2013) 0.83
TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. Oncotarget (2014) 0.82
Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. Front Oncol (2015) 0.82
Methotrexate inhibits the viability of human melanoma cell lines and enhances Fas/Fas-ligand expression, apoptosis and response to interferon-alpha: rationale for its use in combination therapy. Arch Biochem Biophys (2014) 0.81
Malignant melanoma and melanocortin 1 receptor. Biochemistry (Mosc) (2013) 0.81
A Micro/Nano Composite for Combination Treatment of Melanoma Lung Metastasis. Adv Healthc Mater (2016) 0.80
Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines. Cancer Med (2015) 0.80
Small Molecule Inhibitors of Ca(2+)-S100B Reveal Two Protein Conformations. J Med Chem (2016) 0.79
A new model for reimbursing genome-based cancer care. Oncologist (2013) 0.78
Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma. J Transl Med (2015) 0.78
The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK. PLoS One (2015) 0.78
BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis. Blood Cancer J (2015) 0.77
Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival. Front Oncol (2014) 0.76
Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity. Oncotarget (2016) 0.76
Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness Analysis. J Skin Cancer (2015) 0.76
Review of low-grade gliomas in children--evolving molecular era and therapeutic insights. Childs Nerv Syst (2015) 0.76
Post-nano strategies for drug delivery: Multistage porous silicon microvectors. J Mater Chem B Mater Biol Med (2016) 0.75
Dynamic contrast-enhanced MRI perfusion for differentiating between melanoma and lung cancer brain metastases. Cancer Med (2017) 0.75
At the crossroads of targeted treatment and resistance in melanoma. Lancet Oncol (2013) 0.75
BRAFV600E-mutant melanoma presenting with cardiac involvement. J Natl Compr Canc Netw (2014) 0.75
Novel pyrrolidine diketopiperazines selectively inhibit melanoma cells via induction of late-onset apoptosis. J Med Chem (2014) 0.75
Personalized medicine and the clinical laboratory. Einstein (Sao Paulo) (2014) 0.75
Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. Oncoimmunology (2016) 0.75
Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma. Oncogene (2017) 0.75
Mutational analysis of the RAS/RAF/MEK/ERK signaling pathway in 260 Han Chinese patients with cervical carcinoma. Oncol Lett (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Management of cutaneous melanoma. N Engl J Med (2004) 9.52
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res (2005) 6.66
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol (2009) 3.41
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol (2011) 2.45
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med (2011) 2.34
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist (2008) 2.22
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol (2007) 2.19
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer (2014) 2.12
Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings. Radiology (2009) 2.08
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res (2010) 2.03
PD-1 as a potential target in cancer therapy. Cancer Med (2013) 1.98
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res (2007) 1.84
Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother (2005) 1.78
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer (2006) 1.75
Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med (2008) 1.69
The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res (2006) 1.65
State of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 1.58
Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res (2007) 1.57
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol (2003) 1.49
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. J Immunother (2013) 1.48
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
Arterial spin labeling MR imaging for characterisation of renal masses in patients with impaired renal function: initial experience. Eur Radiol (2011) 1.44
Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology (2009) 1.42
Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clin Cancer Res (2006) 1.35
New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol (2003) 1.34
Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol (2008) 1.33
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One (2011) 1.32
The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res (2007) 1.31
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res (2009) 1.30
Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther (2004) 1.29
Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park) (2014) 1.29
GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem (2007) 1.21
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res (2010) 1.19
Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother (2012) 1.18
Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. Radiology (2007) 1.13
Rapid development of hypertension by sorafenib: toxicity or target? Clin Cancer Res (2009) 1.12
Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer (2006) 1.10
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther (2010) 1.10
Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol (2009) 1.10
Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother (2007) 1.10
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol (2012) 1.09
Tissue-based research in kidney cancer: current challenges and future directions. Clin Cancer Res (2008) 1.07
Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. Clin Cancer Res (2007) 1.03
BRAF mutations in metanephric adenoma of the kidney. Eur Urol (2012) 1.02
Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. J Clin Oncol (2009) 1.01
Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol (2003) 1.00
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer (2010) 0.98
A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res (2010) 0.94
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother (2009) 0.93
Immunotherapy of metastatic renal cell carcinoma. Cancer J (2008) 0.93
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. J Transl Med (2009) 0.93
Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response. Semin Oncol (2006) 0.92
Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. Cancer (2012) 0.91
Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol (2014) 0.91
Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance. Expert Rev Anticancer Ther (2007) 0.91
Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol (2013) 0.90
Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis. J Med Econ (2012) 0.89
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. Clin Cancer Res (2007) 0.88
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. J Transl Med (2011) 0.87
Future directions in renal cell carcinoma: 2011 and beyond. Hematol Oncol Clin North Am (2011) 0.87
Immune therapy for kidney cancer: a second dawn? Semin Oncol (2013) 0.86
Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2. J Immunother (2012) 0.86
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. J Transl Med (2010) 0.85
Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer. J Immunother (2002) 0.85
Exploiting regulatory T-cell populations for the immunotherapy of cancer. J Immunother (2007) 0.84
Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma. Melanoma Res (2010) 0.82
Management of metastatic renal cell carcinoma in patients with poor prognosis. Cancer Manag Res (2010) 0.82
Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond. Expert Opin Investig Drugs (2010) 0.81
Chemotherapies and immunotherapies for metastatic kidney cancer. Curr Urol Rep (2005) 0.80
Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urol Oncol (2010) 0.80
Molecular-targeted therapy in malignant melanoma. Expert Rev Anticancer Ther (2009) 0.80
Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. Clin Genitourin Cancer (2009) 0.80
Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients. J Clin Oncol (2012) 0.80
Vemurafenib-induced cardiac tamponade: a rare but potentially life-threatening complication. J Clin Oncol (2013) 0.80
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. J Clin Oncol (2010) 0.79
18th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer. 30 October-2 November 2003, Bethesda, Maryland, USA. Expert Opin Biol Ther (2004) 0.79
Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit? Nat Rev Clin Oncol (2009) 0.78
Refining indications for contemporary surgical treatment of renal cell carcinoma metastatic to the pancreas. HPB (Oxford) (2009) 0.78
Dynamic contrast-enhanced MR imaging for differentiation of renal cell carcinoma subtypes: myth or reality? Radiology (2009) 0.78
Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer (2009) 0.77
Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials. Clin Genitourin Cancer (2006) 0.77
Is interleukin 2 the best initial therapy for many patients with metastatic renal cell carcinoma? Cancer J (2013) 0.77
Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon? Clin Cancer Res (2012) 0.76
Cytokine therapy in melanoma. J Cutan Pathol (2010) 0.76
Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma. Melanoma Res (2011) 0.76
More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma. J Clin Oncol (2007) 0.76